Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lipoic acid choline ester - Novartis

Drug Profile

Lipoic acid choline ester - Novartis

Alternative Names: EV-06; Lipoic acid choline ester 1.5%; Lipoic acid choline ester chloride; Thioctic acid choline ester; UNR 844; UNR844-Cl

Latest Information Update: 16 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Encore Vision
  • Developer Novartis
  • Class Carboxylic acids; Coenzymes; Esters; Eye disorder therapies; Fatty acids; Hepatoprotectants; Quaternary ammonium compounds; Sulfhydryl compounds; Thiophenes
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Presbyopia

Most Recent Events

  • 30 Jun 2021 Novartis initiates a phase II trial in Presbyopia in USA (Ophthalmic) (NCT04806503)
  • 06 Apr 2021 Lipoic acid choline ester is still in phase II trial for Presbyopia in USA (Ophthalmic) (Novartis pipeline, April 2021)
  • 19 Mar 2021 Novartis plans a phase II trial for Presbyopia in May 2021 (NCT04806503)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top